Carvedilol inhibits Kir2.3 channels by interference with PIP₂-channel interaction

Area of Science:

• Pharmacology
• Molecular Biology
• Cardiovascular Research

Background:

• Carvedilol, a dual beta- and alpha-adrenoceptor blocker, is clinically used for heart failure, hypertension, and myocardial infarction.
• Previous studies suggested carvedilol blocks K(ATP) channels by binding to a specific cysteine residue (Cys166) in the pore region.
• Carvedilol reportedly does not affect Kir2.1 channels, which lack this critical Cys166 residue.

Purpose of the Study:

• To elucidate the mechanism by which carvedilol inhibits Kir2.3 potassium channels.
• To compare the potency of carvedilol against Kir2.3 and Kir2.1 channels.
• To investigate the role of phosphatidylinositol 4,5-bisphosphate (PIP2) in carvedilol's interaction with Kir2.3 channels.

Main Methods:

• Electrophysiological recordings were used to measure carvedilol's inhibitory effects on Kir2.3 and Kir2.1 channels.
• Point mutation (I213L) was introduced in Kir2.3 to alter its affinity for PIP2.
• Experiments were conducted with and without exogenous addition of PIP2 to assess its role.

Main Results:

• Carvedilol exhibited significantly higher potency in inhibiting Kir2.3 channels (IC50=0.49 μM) compared to Kir2.1 channels (IC50>50 μM).
• A Kir2.3 mutant (I213L) with increased PIP2 affinity showed reduced sensitivity to carvedilol inhibition (IC50=11.1 μM).
• Exogenous PIP2 application markedly reduced carvedilol's inhibitory effect on Kir2.3 channels (2% inhibition vs. 80% in control).

Conclusions:

• Carvedilol inhibits Kir2.3 channels through a mechanism distinct from its proposed action on K(ATP) channels.
• The findings strongly suggest that carvedilol interferes with the interaction between Kir2.3 channels and PIP2.
• This interaction with PIP2 is a key determinant of carvedilol's potent inhibition of Kir2.3 channels, characteristic of cationic amphiphilic drug action.